03:56 AM EDT, 10/03/2025 (MT Newswires) -- Jazz Pharmaceuticals ( JAZZ ) said Thursday that the US Food and Drug Administration approved Zepzelcain in combination with atezolizumab or atezolizumab and hyaluronidase-tqjs as a maintenance treatment for adults with extensive-stage small cell lung cancer.

The specific indication is patients whose disease has not progressed after first-line induction therapy with other medicines, the company said.

The approval is based on results from a phase 3 clinical trial showing that the Zepzelca-atezolizumab combination reduced the risk of disease progression or death by 46% and the risk of death by 27%, compared to atezolizumab alone, the company said.

Median overall survival for the combination was 13.2 months compared with 10.6 months for atezolizumab alone, the company said.